Amneal Reports Second Quarter 2022 Financial Results
August 5, 2022
‒ Q2 2022 Net Revenue of $559 million; GAAP Net Loss of $121 million; Diluted Loss per Share of $(0.80) ‒
‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.19 ‒
‒ Updates 2022 Adjusted EBITDA guidance ‒
BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2022.
“Solid second quarter results reflect topline growth across all three segments and meaningful acceleration in performance from the first quarter. Our core business is strong as we expect acceleration in the second half of 2022 and further momentum in the years ahead. On the horizon are a number of key catalyst launches in high growth areas that will build upon our strong, diversified core business performance,” said Chirag and Chintu Patel, Co-Chief Executive Officers.
Net revenue in the second quarter of 2022 was $559 million, an increase of 5% compared to $535 million in the second quarter of 2021. The increase was driven by growth across all three segments with solid broad-based performance in Generics, including Injectables, Specialty growth driven by Rytary® and Unithroid®, and the expansion of AvKARE’s distribution channel.
Net loss attributable to Amneal Pharmaceuticals, Inc. was $121 million in the second quarter of 2022 compared to net income of $15 million in the second quarter of 2021. Net loss in the quarter included a pre-tax charge of $263 million for the previously disclosed preliminary settlement of the Opana ER® antitrust litigation. Adjusted EBITDA(1) in the second quarter of 2022 was $135 million, a decrease of 6% compared to the second quarter of 2021, reflective of lower gross profit due to product mix and a tough comparison to the prior year. Diluted loss per share and adjusted diluted EPS(1) in the second quarter of 2022 were $(0.80) and $0.19, respectively, compared to $0.10 and $0.23, respectively, in the second quarter of 2021.
| (1) |
See “Non-GAAP Financial Measures” below. |
Revised Full Year 2022 Guidance
The Company is updating its full year 2022 guidance.
|
|
Revised Full Year 2022 Guidance |
|
Prior Full Year 2022 Guidance |
|
|
Net revenue |
$2.15 billion – $2.25 billion |
|
$2.15 billion – $2.25 billion |
|
|
Adjusted EBITDA (1) |
$500 million – $520 million |
|
$540 million – $560 million |
|
|
Adjusted diluted EPS (2) |
$0.65 – $0.70 |
|
$0.80 – $0.85 |
|
|
Operating cash flow (3) |
$200 million – $225 million |
|
$225 million – $250 million |
|
|
Capital expenditures |
$65 million – $75 million |
|
$75 million – $85 million |
|
|
Weighted average diluted shares outstanding (4) |
Approximately 305 million |
|
Approximately 307 million |
| (1) |
Includes 100% of EBITDA from the AvKARE acquisition. Beginning in the first quarter of 2022, the Company no longer excludes research and development (“R&D”) milestone expense from its non-GAAP financial measures. In the second quarter of 2022 and 2021, R&D milestone expenses were $1 million and $8 million, respectively. Prior periods presented have been revised to reflect this change. Refer to our Form 8-K filed with the Securities and Exchange Commission on May 4, 2022 for a full reconciliation of previously reported non-GAAP results to revised non-GAAP results for prior periods. |
| (2) |
Accounts for 35% non-controlling interest in AvKARE. Beginning in the first quarter of 2022, the Company no longer excludes R&D milestone expense from its non-GAAP financial measures. |
| (3) |
Represents cash provided by operating activities. Guidance does not contemplate one time and non-recurring items such as legal settlements and other discrete items. These amounts exclude anticipated cash payments this year of approximately $131 million related to the preliminary settlement of the Opana ER® antitrust litigation. |
| (4) |
Assumes the weighted average diluted shares outstanding of class A and class B common stock under the if-converted method. |
Amneal’s 2022 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.
Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time on August 5, 2022 to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial (844) 200-6205 (in the U.S.) or (929) 526-1599 (international callers). The access code for the call is 236256. A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 862075.
About Amneal
Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com.
Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance, the Company’s growth prospects and opportunities as well as its strategy for growth; product development and launches; the successful commercialization and market acceptance of new products, and expenditures. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words are intended to identify estimates and forward-looking statements.
The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.
Such risks and uncertainties include, but are not limited to: our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry, in general, specifically from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; our ability to manage our growth through acquisitions and otherwise; our dependence on the sales of a limited number of products for a substantial portion of our total revenues; the continuing trend of consolidation of certain customer groups; our dependence on third-party suppliers and distributors for raw materials for our products and certain finished goods and any associated supply chain disruptions; existing and future legal proceedings, the outcome of which are uncertain and may divert management resources and require us to incur substantial defense or settlement payments and costs; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; the impact of severe weather; the impact of the ongoing COVID-19 pandemic, and the emergence of variant strains; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of product liability and other claims against us by consumers and other third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration (“FDA”) product approval requirements; the impact of healthcare reform and changes in coverage and reimbursement levels by governmental authorities and other third-party payers; our dependence on third-party agreements for a portion of our product offerings; the impact of global economic conditions, including any economic effects stemming from adverse geopolitical events, an economic downturn and inflation rates; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A Common Stock and the fact that we are controlled by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
Non-GAAP Financial Measures
As previously disclosed, beginning in the first quarter of 2022, we no longer exclude research and development milestone expenses related to license and collaboration agreements from our non-GAAP financial measures and our line item components, including adjusted research and development, adjusted EBITDA, adjusted operating income, adjusted net income and adjusted earnings per share. Prior period adjusted results have been revised to reflect this change.
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted earnings per share, adjusted gross profit, adjusted gross margin, adjusted operating income, adjusted cost of goods sold, adjusted selling general and administrative expense, and adjusted research and development expense, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP. The calculation of non-GAAP adjusted diluted earnings per share assumes the conversion of all outstanding shares of class B Common Stock to shares of class A Common Stock under the if-converted method.
Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations and trends while viewing the information through the eyes of management.
These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to net income, diluted earnings per share, gross profit, gross margin, operating income, cost of goods sold, selling general and administrative expense, and research and development expense or any other measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.
A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.
|
Amneal Pharmaceuticals, Inc. |
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
(Unaudited; In thousands, except per share amounts) |
||||||||||||||||
|
|
Three Months Ended |
Six Months Ended |
||||||||||||||
|
|
2022 |
2021 |
2022 |
2021 |
||||||||||||
|
Net revenue |
$ |
559,355 |
|
$ |
535,075 |
|
$ |
1,056,988 |
|
$ |
1,028,180 |
|
||||
|
Cost of goods sold |
|
353,724 |
|
|
322,577 |
|
|
676,786 |
|
|
624,120 |
|
||||
|
Cost of goods sold impairment charges |
|
5,112 |
|
|
— |
|
|
5,112 |
|
|
— |
|
||||
|
Gross profit |
|
200,519 |
|
|
212,498 |
|
|
375,090 |
|
|
404,060 |
|
||||
|
Selling, general and administrative |
|
98,806 |
|
|
86,157 |
|
|
197,471 |
|
|
176,883 |
|
||||
|
Research and development |
|
50,748 |
|
|
52,864 |
|
|
103,546 |
|
|
101,046 |
|
||||
|
In-process research and development impairment charges |
|
— |
|
|
710 |
|
|
— |
|
|
710 |
|
||||
|
Intellectual property legal development expenses |
|
821 |
|
|
1,365 |
|
|
1,585 |
|
|
4,947 |
|
||||
|
Acquisition, transaction-related and integration expenses |
|
241 |
|
|
4,283 |
|
|
675 |
|
|
7,085 |
|
||||
|
Charges related to legal matters, net |
|
251,877 |
|
|
— |
|
|
249,551 |
|
|
— |
|
||||
|
Insurance recoveries for property losses and associated expenses |
|
(1,911 |
) |
|
— |
|
|
(1,911 |
) |
|
— |
|
||||
|
Restructuring and other charges |
|
— |
|
|
— |
|
|
731 |
|
|
363 |
|
||||
|
Change in fair value of contingent consideration |
|
(270 |
) |
|
— |
|
|
(70 |
) |
|
— |
|
||||
|
Other operating income |
|
(1,175 |
) |
|
— |
|
|
(1,175 |
) |
|
— |
|
||||
|
Operating (loss) income |
|
(198,618 |
) |
|
67,119 |
|
|
(175,313 |
) |
|
113,026 |
|
||||
|
Other (expense) income: |
|
|
|
|
||||||||||||
|
Interest expense, net |
|
(35,623 |
) |
|
(34,083 |
) |
|
(68,958 |
) |
|
(67,968 |
) |
||||
|
Foreign exchange loss, net |
|
(5,429 |
) |
|
(2,244 |
) |
|
(7,442 |
) |
|
(156 |
) |
||||
|
Loss on refinancing |
|
(291 |
) |
|
— |
|
|
(291 |
) |
|
— |
|
||||
|
Other income, net |
|
7,230 |
|
|
4,032 |
|
|
9,352 |
|
|
4,826 |
|
||||
|
Total other expense, net |
|
(34,113 |
) |
|
(32,295 |
) |
|
(67,339 |
) |
|
(63,298 |
) |
||||
|
(Loss) income before income taxes |
|
(232,731 |
) |
|
34,824 |
|
|
(242,652 |
) |
|
49,728 |
|
||||
|
Provision for income taxes |
|
7,350 |
|
|
2,648 |
|
|
3,889 |
|
|
3,007 |
|
||||
|
Net (loss) income |
|
(240,081 |
) |
|
32,176 |
|
|
(246,541 |
) |
|
46,721 |
|
||||
|
Less: Net loss (income) attributable to non-controlling interests |
|
119,273 |
|
|
(17,644 |
) |
|
124,015 |
|
|
(25,483 |
) |
||||
|
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest |
|
(120,808 |
) |
|
14,532 |
|
|
(122,526 |
) |
|
21,238 |
|
||||
|
Accretion of redeemable non-controlling interest |
|
— |
|
|
— |
|
|
(438 |
) |
|
— |
|
||||
|
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. |
$ |
(120,808 |
) |
$ |
14,532 |
|
$ |
(122,964 |
) |
$ |
21,238 |
|
||||
|
|
|
|
|
|
||||||||||||
|
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s class A common stockholders: |
|
|
|
|
||||||||||||
|
Basic |
$ |
(0.80 |
) |
$ |
0.10 |
|
$ |
(0.82 |
) |
$ |
0.14 |
|
||||
|
Diluted |
$ |
(0.80 |
) |
$ |
0.10 |
|
$ |
(0.82 |
) |
$ |
0.14 |
|
||||
|
Weighted-average common shares outstanding: |
|
|
|
|
||||||||||||
|
Basic |
|
150,993 |
|
|
148,996 |
|
|
150,445 |
|
|
148,507 |
|
||||
|
Diluted |
|
150,993 |
|
|
151,986 |
|
|
150,445 |
|
|
151,606 |
|
||||
|
Amneal Pharmaceuticals, Inc. |
||||||||
|
Condensed Consolidated Balance Sheets |
||||||||
|
(Unaudited; In thousands) |
||||||||
|
|
June 30, 2022 |
|
December 31, 2021 |
|||||
|
Assets |
|
|
|
|||||
|
Current assets: |
|
|
|
|||||
|
Cash and cash equivalents |
$ |
91,979 |
|
$ |
247,790 |
|||
|
Restricted cash |
|
6,203 |
|
|
|
8,949 |
|
|
|
Trade accounts receivable, net |
|
688,849 |
|
|
|
662,583 |
|
|
|
Inventories |
|
533,028 |
|
|
|
489,389 |
|
|
|
Prepaid expenses and other current assets |
|
232,204 |
|
|
|
110,218 |
|
|
|
Related party receivables |
|
1,338 |
|
|
|
1,179 |
|
|
|
Total current assets |
|
1,553,601 |
|
|
|
1,520,108 |
|
|
|
Property, plant and equipment, net |
|
483,625 |
|
|
|
514,158 |
|
|
|
Goodwill |
|
600,974 |
|
|
|
593,017 |
|
|
|
Intangible assets, net |
|
1,204,224 |
|
|
|
1,166,922 |
|
|
|
Operating lease right-of-use assets |
|
36,490 |
|
|
|
39,899 |
|
|
|
Operating lease right-of-use assets – related party |
|
19,212 |
|
|
|
20,471 |
|
|
|
Financing lease right-of-use assets |
|
63,443 |
|
|
|
64,475 |
|
|
|
Other assets |
|
79,836 |
|
|
|
20,614 |
|
|
|
Total assets |
$ |
4,041,405 |
|
|
$ |
3,939,664 |
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|||||
|
Current liabilities: |
|
|
|
|||||
|
Accounts payable and accrued expenses |
$ |
561,692 |
|
|
$ |
525,345 |
|
|
|
Current portion of liabilities for legal matters |
|
275,338 |
|
|
|
58,000 |
|
|
|
Revolving credit facility |
|
85,000 |
|
|
|
— |
|
|
|
Current portion of long-term debt, net |
|
29,920 |
|
|
|
30,614 |
|
|
|
Current portion of operating lease liabilities |
|
10,096 |
|
|
|
9,686 |
|
|
|
Current portion of operating and financing lease liabilities – related party |
|
2,796 |
|
|
|
2,636 |
|
|
|
Current portion of financing lease liabilities |
|
3,318 |
|
|
|
3,101 |
|
|
|
Related party payables – short term |
|
24,904 |
|
|
|
47,861 |
|
|
|
Total current liabilities |
|
993,064 |
|
|
|
677,243 |
|
|
|
Long-term debt, net |
|
2,622,447 |
|
|
|
2,680,053 |
|
|
|
Note payable – related party |
|
38,856 |
|
|
|
38,038 |
|
|
|
Operating lease liabilities |
|
28,904 |
|
|
|
32,894 |
|
|
|
Operating lease liabilities – related party |
|
17,380 |
|
|
|
18,783 |
|
|
|
Financing lease liabilities |
|
60,011 |
|
|
|
60,251 |
|
|
|
Related party payables – long term |
|
10,654 |
|
|
|
9,619 |
|
|
|
Other long-term liabilities |
|
79,213 |
|
|
|
38,903 |
|
|
|
Total long-term liabilities |
|
2,857,465 |
|
|
|
2,878,541 |
|
|
|
Redeemable non-controlling interests |
|
17,885 |
|
|
|
16,907 |
|
|
|
Total stockholders’ equity |
|
172,991 |
|
|
|
366,973 |
|
|
|
Total liabilities and stockholders’ equity |
$ |
4,041,405 |
|
|
$ |
3,939,664 |
|
|
|
Amneal Pharmaceuticals, Inc. |
||||||||
|
Consolidated Statements of Cash Flows |
||||||||
|
(Unaudited; In thousands) |
||||||||
|
|
Six Months Ended June 30, |
|||||||
|
|
2022 |
2021 |
||||||
|
Cash flows from operating activities: |
|
|
||||||
|
Net (loss) income |
$ |
(246,541 |
) |
$ |
46,721 |
|
||
|
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: |
|
|
||||||
|
Depreciation and amortization |
|
117,511 |
|
|
112,037 |
|
||
|
Unrealized foreign currency loss |
|
8,014 |
|
|
124 |
|
||
|
Amortization of debt issuance costs and discount |
|
4,388 |
|
|
4,473 |
|
||
|
Loss on refinancing |
|
291 |
|
|
— |
|
||
|
Intangible asset impairment charges |
|
5,112 |
|
|
710 |
|
||
|
Insurance recoveries for property and equipment losses |
|
(1,000 |
) |
|
— |
|
||
|
Stock-based compensation |
|
16,327 |
|
|
12,962 |
|
||
|
Inventory provision |
|
17,748 |
|
|
25,805 |
|
||
|
Change in fair value of contingent consideration |
|
(70 |
) |
|
— |
|
||
|
Other operating charges and credits, net |
|
3,449 |
|
|
2,764 |
|
||
|
Changes in assets and liabilities: |
|
|
||||||
|
Trade accounts receivable, net |
|
(26,561 |
) |
|
(13,167 |
) |
||
|
Inventories |
|
(65,395 |
) |
|
(54,580 |
) |
||
|
Prepaid expenses, other current assets and other assets |
|
(119,747 |
) |
|
(23,988 |
) |
||
|
Related party receivables |
|
(159 |
) |
|
7,383 |
|
||
|
Accounts payable, accrued expenses and other liabilities |
|
273,947 |
|
|
(21,137 |
) |
||
|
Related party payables |
|
7,508 |
|
|
(3,912 |
) |
||
|
Net cash (used in) provided by operating activities |
|
(5,178 |
) |
|
96,195 |
|
||
|
Cash flows from investing activities: |
|
|
||||||
|
Purchases of property, plant and equipment |
|
(15,842 |
) |
|
(19,585 |
) |
||
|
Deposits for future acquisition of property, plant, and equipment |
|
(3,955 |
) |
|
(1,667 |
) |
||
|
Acquisition of intangible assets |
|
(10,000 |
) |
|
(500 |
) |
||
|
Acquisitions of businesses, net of cash acquired |
|
(84,714 |
) |
|
(73,828 |
) |
||
|
Proceeds from insurance recoveries for property and equipment losses |
|
1,000 |
|
|
— |
|
||
|
Net cash used in investing activities |
|
(113,511 |
) |
|
(95,580 |
) |
||
|
Cash flows from financing activities: |
|
|
||||||
|
Payments of deferred financing and refinancing costs |
|
(1,622 |
) |
|
— |
|
||
|
Payments of principal on debt, financing leases and other |
|
(63,010 |
) |
|
(33,876 |
) |
||
|
Borrowings on revolving credit facility |
|
85,000 |
|
|
— |
|
||
|
Proceeds from exercise of stock options |
|
239 |
|
|
681 |
|
||
|
Employee payroll tax withholding on restricted stock unit vesting |
|
(3,291 |
) |
|
(2,378 |
) |
||
|
Tax distributions to non-controlling interests |
|
(9,917 |
) |
|
(27,551 |
) |
||
|
Acquisition of redeemable non-controlling interest |
|
(1,722 |
) |
|
— |
|
||
|
Payments of deferred consideration for acquisitions – related party |
|
(43,998 |
) |
|
— |
|
||
|
Payments of principal on financing lease – related party |
|
— |
|
|
(93 |
) |
||
|
Repayment of related party note |
|
— |
|
|
(1,000 |
) |
||
|
Net cash used in financing activities |
|
(38,321 |
) |
|
(64,217 |
) |
||
|
Effect of foreign exchange rate on cash |
|
(1,547 |
) |
|
(366 |
) |
||
|
Net decrease in cash, cash equivalents, and restricted cash |
|
(158,557 |
) |
|
(63,968 |
) |
||
|
Cash, cash equivalents, and restricted cash – beginning of period |
|
256,739 |
|
|
347,121 |
|
||
|
Cash, cash equivalents, and restricted cash – end of period |
$ |
98,182 |
|
$ |
283,153 |
|
||
|
Cash and cash equivalents – end of period |
$ |
91,979 |
|
$ |
278,306 |
|
||
|
Restricted cash – end of period |
|
6,203 |
|
|
4,847 |
|
||
|
Cash, cash equivalents, and restricted cash – end of period |
$ |
98,182 |
|
$ |
283,153 |
|
||
|
Amneal Pharmaceuticals, Inc. |
||||||||||||||||
|
Non-GAAP Reconciliations |
||||||||||||||||
|
(Unaudited, In thousands) |
||||||||||||||||
|
Reconciliation of Net (Loss) Income to EBITDA and Adjusted EBITDA (1) |
||||||||||||||||
|
|
Three Months Ended June 30, |
Six Months Ended June 30, |
||||||||||||||
|
|
2022 |
2021 |
2022 |
2021 |
||||||||||||
|
Net (loss) income |
$ |
(240,081 |
) |
$ |
32,176 |
$ |
(246,541 |
) |
$ |
46,721 |
||||||
|
Adjusted to add: |
|
|
|
|
||||||||||||
|
Interest expense, net |
|
35,623 |
|
|
34,083 |
|
|
68,958 |
|
|
67,968 |
|
||||
|
Provision for income taxes |
|
7,350 |
|
|
2,648 |
|
|
3,889 |
|
|
3,007 |
|
||||
|
Depreciation and amortization |
|
59,696 |
|
|
56,487 |
|
|
117,511 |
|
|
112,037 |
|
||||
|
EBITDA (Non-GAAP) |
$ |
(137,412 |
) |
$ |
125,394 |
|
$ |
(56,183 |
) |
$ |
229,733 |
|
||||
|
Adjusted to add (deduct): |
|
|
|
|
||||||||||||
|
Stock-based compensation expense |
|
8,262 |
|
|
7,632 |
|
|
16,327 |
|
|
12,962 |
|
||||
|
Acquisition, site closure, and idle facility expenses (2) |
|
3,173 |
|
|
5,964 |
|
|
8,762 |
|
|
11,756 |
|
||||
|
Restructuring and other charges (3) |
|
— |
|
|
— |
|
|
731 |
|
|
363 |
|
||||
|
Loss on refinancing |
|
291 |
|
|
— |
|
|
291 |
|
|
— |
|
||||
|
Inventory related charges |
|
— |
|
|
87 |
|
|
— |
|
|
201 |
|
||||
|
Charges related to legal matters, net (4) |
|
251,877 |
|
|
— |
|
|
249,551 |
|
|
— |
|
||||
|
Asset impairment charges |
|
5,250 |
|
|
741 |
|
|
5,250 |
|
|
1,064 |
|
||||
|
Foreign exchange loss |
|
5,429 |
|
|
2,244 |
|
|
7,442 |
|
|
156 |
|
||||
|
Regulatory approval milestone |
|
— |
|
|
— |
|
|
5,000 |
|
|
— |
|
||||
|
Change in fair value of contingent consideration |
|
(270 |
) |
|
— |
|
|
(70 |
) |
|
— |
|
||||
|
Insurance recoveries for property losses and associated expenses |
|
(1,911 |
) |
|
— |
|
|
(1,911 |
) |
|
— |
|
||||
|
Other |
|
(104 |
) |
|
807 |
|
|
(745 |
) |
|
1,806 |
|
||||
|
Adjusted EBITDA (Non-GAAP) |
$ |
134,585 |
|
$ |
142,869 |
|
$ |
234,445 |
|
$ |
258,041 |
|
||||
Contacts
Anthony DiMeo
Head of Investor Relations
[email protected]